Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors
Papulopustular rash (PPR) is the most frequent cutaneous adverse event during treatment with epidermal growth factor receptor inhibitors (EGFRis). Although often mild in severity, it can impair patients’ quality of life and may also be a reason for discontinuing or changing the dose of the antineopl...
Main Authors: | Eleonora De Luca, Pietro Sollena, Lucia Di Nardo, Ettore D’Argento, Emanuele Vita, Giampaolo Tortora, Ketty Peris |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2024-01-01
|
Series: | Dermatology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2024/8859032 |
Similar Items
-
Papulopustular Facial Eruption in a Child: A Quiz
by: Louise Parke, et al.
Published: (2019-04-01) -
Erlotinib-Induced Papulopustular Eruption and Mucositis
by: Zehra Aşiran Serdar, et al.
Published: (2018-07-01) -
Papulopustular eruptions of bilateral soles with facial erythematous papuloplaques in a 44-year-old female
by: Chih-Hsiang Chang, et al.
Published: (2010-06-01) -
“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
by: Pietro Sollena, et al.
Published: (2022-05-01) -
The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions
by: Mauro Bavetta, et al.
Published: (2021-01-01)